v3.26.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Cash flows from operating activities:              
Net loss $ (6,009,447) $ (3,402,264) $ (3,607,361) $ (3,063,997) $ (12,234,082) $ (13,391,931)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation expense         1,000 1,500  
Amortization of intangible assets         1,361,539  
Change in fair value of warrant liability         35,214 (781,311)  
Change in fair value of derivative liability   (2,356,428)   (2,296,834)  
Loss on conversion of note payable   (43,200)   53,446  
Loss on disposition of subsidiaries         214,486  
Stock-based compensation         332,725 1,820,433  
Common stock issued for services         4,223,490  
Amortization of debt discount         236,277 2,749,989  
Amortization of right-of-use assets         27,212 35,935  
Interest income (93,750)       (281,250) (62,500)  
Changes in operating assets and liabilities:              
Accounts receivable, net         (1,488,773) (570,799)  
Prepaid expenses and deposits         (119,909) (214,212)  
Inventory         (784,701) (234,521)  
Deferred offering costs         47,384 (80,469)  
Lease liability         (27,373) (36,979)  
Accounts payable         2,699,199 657,170  
Accrued liabilities         1,281,492 (285,841)  
Current liability         (5,441)  
Development liability         (600,000)  
Net cash used in operating activities         (9,514,046) (8,204,389)  
Cash flows from financing activities:              
Proceeds from loan payable, related party         116,000  
Proceeds from issuance of note payable, net of issuance costs         10,590,000  
Repayment of convertible notes         (3,333,333)  
Gross proceeds from issuance of common stock         39,562 11,469,318  
Net cash provided by financing activities         10,629,562 8,251,985  
Net change in cash, cash equivalents and restricted cash         1,115,516 47,596  
Total cash, cash equivalents and restricted cash at beginning of period   6,662,008   308,096 6,662,008 308,096 $ 308,096
Total cash, cash equivalents and restricted cash at end of period 7,777,524   355,692   7,777,524 355,692 6,662,008
Beginning of period:              
Cash and cash equivalents   6,662,008   308,096 6,662,008 308,096 308,096
Restricted cash    
End of period:              
Cash and cash equivalents 4,747,439   355,692   4,747,439 355,692 6,662,008
Restricted cash $ 3,030,085     3,030,085
Supplemental disclosure of cash flow information:              
Cash paid for interest         60,482  
Cash paid for taxes          
Supplemental disclosure of non-cash investing and financing activities:              
Conversion of note payable into common stock         411,000  
Equity line of commitment shares issued as offering costs         1,526,318  
Issuance of note receivable in exchange for other receivables         5,000,000  
Original issue discount and transaction expenses withheld from note payable principal         420,000  
Right-of-use asset obtained in exchange for operating lease liability         167,967  
Common stock issued for subscription receivable         $ 484,995